文献速递消化道肿瘤放疗姑息放疗与转移瘤

短程放疗联合化疗治疗寡转移性直肠腺癌:原发灶局部完全缓解者采取非手术意图

Oligometastatic Rectal Adenocarcinoma Treated With Short-Course Radiation Therapy and Chemotherapy With Nonoperative Intent of the Primary for Locoregional Complete Responders.
PubMed 文献 · Pract Radiat Oncol · 2022-05-05

本单机构回顾性分析评估36例新诊断寡转移性直肠癌患者接受短程放疗联合化疗(SCRT-CTX)并以非手术意图处理原发灶,其中17%(6/36)达局部临床完全缓解(cCR),11%(4例)出现局部失败,全组12个月和24个月总生存率分别为83%和57%,因梗阻、直肠出血或需永久性造口而住院的比例较低。

要点

  • SCRT-CTX后17%(6/36)患者达局部cCR,11%(4例)出现局部失败。
  • 全组12个月和24个月OS分别为83%(71%-96%)和57%(41%-80%)。
  • 化疗超过4个月和转移灶根治性治疗是多变量分析中改善OS的预测因素。

核心结论

  • 对局部cCR的新诊断寡转移性直肠腺癌患者,以非手术意图给予SCRT-CTX可能是合理的治疗选择,并显示对盆腔疾病和症状的良好控制。
  • 在治疗范式中延长化疗持续时间可能改善肿瘤学结局。

研究设计与样本

  • 单机构回顾性分析,纳入2018年1月1日至2020年5月31日间新诊断的寡转移性直肠癌患者36例,均接受SCRT-CTX并以非手术意图处理原发灶。
  • 通过直肠指检、内镜和影像学(计算机断层扫描或磁共振成像)判定cCR;可手术但未达cCR者行原发直肠肿瘤手术切除;达cCR后出现局部失败者接受挽救手术。

主要发现

  • 17%(6/36)患者在SCRT-CTX后达cCR,11%(4例)患者出现局部失败。
  • 全组12个月OS为83%(71%-96%),24个月OS为57%(41%-80%)。
  • 全组12个月无进展生存率为56%(41%-74%),24个月为10%(3.1%-35%)。
  • 多变量分析中,接受超过4个月化疗(风险比=0.21;95%置信区间,0.06-0.71;P=0.01)和转移灶根治性治疗(风险比=0.17;95%置信区间,0.05-0.66;P=0.01)预测OS改善。
  • 因梗阻(8/36,22%)、直肠出血(5/36,14%)或需永久性造口(5/36,14%)而住院的患者数低,且完成SCRT-CTX后梗阻症状和直肠出血的主诉减少。

临床怎么用

  • 对局部cCR的新诊断寡转移性直肠腺癌患者,以非手术意图给予SCRT-CTX可能是合理的治疗选择。
  • 作者认为,在治疗范式中延长化疗持续时间可能改善肿瘤学结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Nonoperative management with short-course radiation therapy (SCRT) as a component of definitive therapy for oligometastatic rectal cancer has not been previously reported. This single-institution retrospective analysis evaluates treatment with SCRT in combination with chemotherapy (SCRT-CTX) with nonoperative intent for patients with a locoregional clinical complete response (cCR). METHODS AND MATERIALS: Thirty-six patients with newly diagnosed oligometastatic rectal cancer were treated with SCRT-CTX between January 1, 2018, and May 31, 2020. Digital rectal examination, endoscopy, and imaging (computed tomography or magnetic resonance imaging) were used to determine cCR. Medically operable patients without cCR underwent surgical resection of the primary rectal tumor. Patients with cCR who experienced a local failure received salvage surgery. Rates of hospitalization related to primary tumor disease and pelvic symptoms were reviewed. Overall survival (OS) and progression free survival were evaluated. RESULTS: Seventeen percent (6/36) of patients achieved cCR after SCRT-CTX. Eleven percent (4) of patients experienced a local failure. OS for all patients was 83% (71%-96%) at 12 months and 57% (41%-80%) at 24 months. Progression free survival for all patients was 56% (41%-74%) at 12 months and 10% (3.1%-35%) at 24 months. On multivariate analysis, having received more than 4 months of chemotherapy (hazard ratio = 0.21; 95% confidence interval, 0.06-0.71; P = .01) and definitive treatment of metastatic site (hazard ratio = 0.17; 95% confidence interval, 0.05-0.66; P = .01) predicted for improved OS. The number of patients requiring hospitalization due to obstruction (8/36, 22%), rectal bleeding (5/36, 14%), or need for permanent ostomy placement (5/36, 14%) was low, and there was a decrease in endorsement of obstructive symptoms and rectal bleeding after completion of SCRT-CTX. CONCLUSIONS: SCRT-CTX with nonoperative intent for patients with a locoregional cCR may be a reasonable treatment option for patients with newly diagnosed oligometastatic rectal adenocarcinoma and demonstrates excellent control of pelvic disease and symptoms. Increased duration of chemotherapy within the treatment paradigm may improve oncologic outcomes.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Schiff JP, Chin RI, Roy A, et al. Oligometastatic Rectal Adenocarcinoma Treated With Short-Course Radiation Therapy and Chemotherapy With Nonoperative Intent of the Primary for Locoregional Complete Responders. Pract Radiat Oncol. 2022. PMID: 35526826. doi:10.1016/j.prro.2022.04.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。